Sichuan Huiyu Seacross Pharma Technology Ltd.

Primary objectives: To evaluate the safety and tolerability of HYP-6589 monotherapy in the treatment of advanced solid tumors; to determine the recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD) of HYP-6589 in the treatment of patients with advanced solid tumors.

The main purpose of dose escalation is to evaluate the safety and tolerability of HY07121 for injection in the treatment of patients with advanced malignant solid tumors; to explore the maximum tolerated dose (MTD) and provide a recommended dose (RP2D) and a reasonable dosing regimen for Phase II or subsequent clinical studies. The main purpose of dose expansion is to evaluate the anti-tumor efficacy of HY07121 for injection.

The main purpose of the study is to compare the pharmacokinetic characteristics of the ferric carboxymaltose injection (10mL: 500mg (in terms of iron)) provided by Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. and the ferric carboxymaltose injection (trade name: Ferinject®, specification: 10mL: 500mg (in terms of iron)) held by Vifor France in subjects with iron deficiency anemia under fasting conditions, and to preliminarily evaluate the bioequivalence of the two preparations. The secondary purpose of the study is to evaluate the safety of the ferric carboxymaltose injection (10mL: 500mg (in terms of iron)) provided by Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. under fasting conditions.